Vaxdigm Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 10

Vaxdigm General Information

Description

Operator of a biotechnology company designed to advance the development of improved and vaccines. The company's platform offers innovative vaccine methodologies, enabling healthcare providers and researchers to address current and emerging health threats effectively.

Contact Information

Website
www.vaxdigm.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 306c, 3rd Floor, 37, Seongsu-iro 22-gil
  • Seongdong-gu, 2-ga, Arc Valley
  • Seoul
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 306c, 3rd Floor, 37, Seongsu-iro 22-gil
  • Seongdong-gu, 2-ga, Arc Valley
  • Seoul
  • South Korea
+82

Vaxdigm Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vaxdigm Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Accelerator/Incubator Completed Generating Revenue
5. Early Stage VC (Series A) 22-Oct-2024 Completed Generating Revenue
4. Accelerator/Incubator Completed Generating Revenue
3. Early Stage VC 01-Aug-2023 Completed Generating Revenue
2. Accelerator/Incubator 06-Oct-2022 Completed Generating Revenue
1. Seed Round 09-May-2022 Completed Generating Revenue
To view Vaxdigm’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Vaxdigm Patents

  • 9

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

Vaxdigm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4530292-A1 Crystalline-protein-based platform using viral nucleocapsid for producing target-protein-fused self-assembled nanoparticles Inactive 23-May-2022
US-20260193661-A1 Crystalline-protein-based platform using viral nucleocapsid for producing target-protein-fused self-assembled nanoparticles Pending 23-May-2022
WO-2023229329-A1 Crystalline-protein-based platform using viral nucleocapsid for producing target-protein-fused self-assembled nanoparticles Inactive 23-May-2022
EP-4530352-A1 Pentameric toxin protein-based target protein fusion pentamer producing platform using viral nucleocapsid Inactive 23-May-2022
US-20260184745-A1 Pentameric toxin protein-based target protein fusion pentamer producing platform using viral nucleocapsid Pending 23-May-2022 C07K14/25
To view Vaxdigm’s complete patent history, request access »

Vaxdigm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vaxdigm Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Find Us Accelerator/Incubator Minority
Findus Venture Venture Capital Minority
iAccel (Seongnam-si) Venture Capital Minority
InfoBank Venture Capital Minority
Korea Alternative Investment Corporation Asset Manager Minority
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

Vaxdigm FAQs

  • When was Vaxdigm founded?

    Vaxdigm was founded in 2021.

  • Where is Vaxdigm headquartered?

    Vaxdigm is headquartered in Seoul, South Korea.

  • What is the size of Vaxdigm?

    Vaxdigm has 10 total employees.

  • What industry is Vaxdigm in?

    Vaxdigm’s primary industry is Drug Discovery.

  • Is Vaxdigm a private or public company?

    Vaxdigm is a Private company.

  • What is Vaxdigm’s current revenue?

    The current revenue for Vaxdigm is .

  • How much funding has Vaxdigm raised over time?

    Vaxdigm has raised $2.4M.

  • Who are Vaxdigm’s investors?

    Find Us, Findus Venture, iAccel (Seongnam-si), InfoBank, and Korea Alternative Investment Corporation are 5 of 10 investors who have invested in Vaxdigm.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process